Calidi Biotherapeutics (Calidi Biotherapeutics) LT-Debt-to-Total-Asset : 0.86 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Calidi Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.86.

Calidi Biotherapeutics's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.86). It may suggest that Calidi Biotherapeutics is progressively becoming more dependent on debt to grow their business.

Calidi Biotherapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Calidi Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics LT-Debt-to-Total-Asset Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

3.48

0.01

0.17

0.53

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					-	0.36	0.29	0.53	0.86

Calidi Biotherapeutics LT-Debt-to-Total-Asset Calculation

Calidi Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5.313	/	10.019
	=

Calidi Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	6.328	/	7.405
	=

Calidi Biotherapeutics (AMEX:CLDI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Calidi Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024